Pacific Edge Limited ( (PFGTF) ) has released its Q2 earnings. Here is a breakdown of the information Pacific Edge Limited presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pacific Edge Limited is a New Zealand-based company specializing in the research, development, and commercialization of diagnostic and prognostic tools for early cancer detection, with a focus on bladder cancer diagnostics. The company operates laboratories in New Zealand and the USA and is listed on both the NZX and ASX.
In its latest earnings report for the six months ending September 2025, Pacific Edge Limited reported a significant decline in revenue, largely due to the loss of Medicare coverage for its Cxbladder tests in the US. The company generated total revenue and other income of $7.123 million, down from $12.155 million in the same period last year. This decline has contributed to a net loss after tax of $19.116 million, compared to a loss of $14.503 million in the previous year.
Key financial metrics indicate that operating expenses remained relatively stable at $26.239 million, with significant costs attributed to research and development, sales and marketing, and general administration. The company issued additional shares during the period, raising $19.548 million, which contributed to an increase in share capital. Despite these efforts, the company’s net tangible assets per share decreased to $0.026 from $0.049 in the previous year.
Looking forward, Pacific Edge Limited is actively pursuing avenues to regain Medicare coverage, which is critical for improving its financial performance. The company is appealing denied Medicare claims and seeking reconsideration requests with the Medicare Administrative Contractor. Successful re-coverage could significantly enhance revenue generation and stabilize the company’s financial outlook.
Overall, while Pacific Edge faces challenges due to the loss of Medicare coverage, its management remains focused on strategic initiatives to secure additional funding and reduce cash burn, aiming to sustain operations and achieve long-term growth.